Skip to main content

Market Overview

Kamada Reports Top-line Data Of Plasma-Derived IgG Treatment From Early-Stage COVID-19 Trial

Share:

Kamada Ltd (NASDAQ: KMDA) has announced top-line results from its Phase 1/2 trial in Israel evaluating plasma-derived hyperimmune globulin (IgG) treatment for COVID-19.

  • Kamada had announced the interim results from the study in September last year.
  • A total of 12 eligible patients were enrolled and received a single dose of 4 grams within three to 10 days of initial symptoms. The patients were followed for 84 days post-treatment.
  • As previously reported, 11 of the 12 patients recovered following the treatment. Seven patients were discharged from the hospital at or before day five post-treatment, and the remaining four patients were discharged by day 9.
  • Following the infusion of the product, anti-SARS CoV-2 IgG levels in the plasma of all patients increased.
  • The effect of the treatment on neutralization activity is further analyzed. However, interim data demonstrated that the IgG level increase was associated with enhanced neutralization activity.
  • The treatment showed a favorable safety profile, and there were no infusion-related reactions or adverse events.
  • Two serious adverse events in the study were reported. Both were considered not related to the study drug.
  • One patient died on day 37 post-treatment due to complications from COVID-19.
  • One patient was diagnosed post-discharge with pulmonary embolism on day 7 of the study. The patient was re-hospitalized, treated with anticoagulation therapy, recovered within two days.
  • The initial order from the Israeli Ministry of Health for the product is sufficient to treat approximately 500 hospitalized patients and is expected to generate roughly $3.4 million in revenue for Kamada.
  • Israeli Ministry of Health is conducting a clinical study comparing Kamada's product to convalescent plasma in hospitalized patients.
  • Though earlier this month, the National Institutes of Health halted a trial evaluating the safety and effectiveness of COVID-19 convalescent plasma as it found no benefit.
  • Price Action: KMDA shares are trading 1.82% higher at $6.14 in premarket trading on the last check Wednesday.
 

Related Articles (KMDA)

View Comments and Join the Discussion!

Posted-In: Covid-19 israel Phase 1 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com